Rowland Noakes
Research Subjects
Rowland Noakes has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Tim Aung
Bond University, Gold Coast, QLD, Australia; GPCU, University of Queensland, Brisbane, QLD, Australia; Star Medical Centre - Woodridge, Logan Central, QLD, Australia
3 shared publications - Dedee Frances Murrell
Department of Dermatology, St George Hospital, Sydney, Australia
2 shared publications - Kais Kasem
Clinical Pathology Department University of Melbourne Melbourne Victoria Australia
2 shared publications - Awatef Kelati
Dermatology Department University Hospital Cheikh Khalifa, and the University Hospital Mohammed VI. Faculty of Medicine, Mohammed VI University of Health and Sciences (UM6SS) Casablanca Morocco
1 shared publication - Benjamin Silas Daniel
Department of Dermatology Royal Children's Hospital Melbourne Parkville Victoria Australia
1 shared publication L. Spelman
South East Dermatology
1 shared publication
Latest Publications
- 27 February 2026
- Published by SAGE Publications in International Journal of Tryptophan Research
- Vol. 19
An Ecofriendly L-Tryptophan Containing UVA-1 Permissive Sunscreen Formulation: A Novel Approach for Inflammatory and Fibrosing Skin Diseases
UVA-1 phototherapy, used in the management of psoriasis, atopic dermatitis and fibrosing skin disorders has been reported to mediate part of its therapeutic benefit via aryl hydrocarbon receptor (AHR) signalling. Accessibility to therapy remains limited and a cost-effective topical preparation permissive of UVA-1 transmission at therapeutic doses whilst offering photoprotection in the UVB and UVA-2 spectra and activity at the AHR would represent a notable therapeutic advance. The amino acid L-tryptophan absorbs maximally at 280 nm with absorbance falling rapidly to 310 nm potentially providing photoprotection in the UVB spectrum. In addition, this amino acid is photo-oxidized to 6-formylindolo[3,2-b] carbazole (FICZ), a potent endogenous ligand of the AHR and is thus a potential candidate for inclusion. Lecithin absorbs UV light in a broad band from 200 to 380 nm with peak absorbance at 235, 271 and 355 nm and has potential as a biodegradable and ecofriendly sunscreen with an efficacy equivalent to traditional sunscreens. A proof-of-concept study was performed to assess whether a topical solution of L-tryptophan formulated to favour the generation of FICZ on photoactivation demonstrated activity at the aryl hydrocarbon receptor (AHR) as assessed by the intensity of cytochrome P450 1A2 staining. Ten participants applied a trial agent consisting of 2% L-tryptophan, 30% sunflower lecithin, 3% polyvinyl alcohol, 20% ethanol, pH 5.8 followed by 36 sessions of progressively graduated sun exposure increasing to a total of 20 J/cm 2 as determined by UV integrator over a period 12 weeks. At the end of the trial, biopsies were taken from treated sites and assessed by the intensity of cytochrome P450 1A2 staining. Photo protected skin from the buttock was used as a control. An average baseline value of 53 488 923 units was obtained at the control site and 972 214 294 at the treatment site supporting the concept that this preparation displays activity at the AHR.
- 27 February 2026
- Published by SAGE Publications in International Journal of Tryptophan Research
- Vol. 19
An Ecofriendly L-Tryptophan Containing UVA-1 Permissive Sunscreen Formulation: A Novel Approach for Inflammatory and Fibrosing Skin Diseases
UVA-1 phototherapy, used in the management of psoriasis, atopic dermatitis and fibrosing skin disorders has been reported to mediate part of its therapeutic benefit via aryl hydrocarbon receptor (AHR) signalling. Accessibility to therapy remains limited and a cost-effective topical preparation permissive of UVA-1 transmission at therapeutic doses whilst offering photoprotection in the UVB and UVA-2 spectra and activity at the AHR would represent a notable therapeutic advance. The amino acid L-tryptophan absorbs maximally at 280 nm with absorbance falling rapidly to 310 nm potentially providing photoprotection in the UVB spectrum. In addition, this amino acid is photo-oxidized to 6-formylindolo[3,2-b] carbazole (FICZ), a potent endogenous ligand of the AHR and is thus a potential candidate for inclusion. Lecithin absorbs UV light in a broad band from 200 to 380 nm with peak absorbance at 235, 271 and 355 nm and has potential as a biodegradable and ecofriendly sunscreen with an efficacy equivalent to traditional sunscreens. A proof-of-concept study was performed to assess whether a topical solution of L-tryptophan formulated to favour the generation of FICZ on photoactivation demonstrated activity at the aryl hydrocarbon receptor (AHR) as assessed by the intensity of cytochrome P450 1A2 staining. Ten participants applied a trial agent consisting of 2% L-tryptophan, 30% sunflower lecithin, 3% polyvinyl alcohol, 20% ethanol, pH 5.8 followed by 36 sessions of progressively graduated sun exposure increasing to a total of 20 J/cm 2 as determined by UV integrator over a period 12 weeks. At the end of the trial, biopsies were taken from treated sites and assessed by the intensity of cytochrome P450 1A2 staining. Photo protected skin from the buttock was used as a control. An average baseline value of 53 488 923 units was obtained at the control site and 972 214 294 at the treatment site supporting the concept that this preparation displays activity at the AHR.
- Open Access
- 18 July 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (6) , 364-368
Linear Focal Elastosis: What We Know From Epidemiological Studies
Linear focal elastosis (LFE), characterised by horizontal streaks on the lower back, is a dermatological condition with unclear etiopathogenesis and limited epidemiological data. This study synthesises case reports to elucidate demographic patterns, clinical manifestations, and potential associations. A literature search across PubMed, Embase, Ovid and ResearchGate identified 37 relevant articles, yielding 80 cases after excluding duplicates and irrelevant articles. In analysis, the male‐to‐female ratio for LFE was 5:1, with a mean age of 39 years. Cases were more common among adolescents and older adults (age ≥ 60), with the majority occurring in pubertal adolescents. No racial predilection was observed. The lower back was the most frequently affected site, with rare cases involving other body parts. Some cases were associated with growth spurts or strenuous exercise, although the etiopathogenesis remains speculative. LFE may be underreported due to its asymptomatic nature and resemblance to other skin conditions, particularly striae distensae. Further research is required to clarify its pathogenesis and explore potential treatment options.
- 18 July 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (6) , 364-368
Open AccessLinear Focal Elastosis: What We Know From Epidemiological Studies
Linear focal elastosis (LFE), characterised by horizontal streaks on the lower back, is a dermatological condition with unclear etiopathogenesis and limited epidemiological data. This study synthesises case reports to elucidate demographic patterns, clinical manifestations, and potential associations. A literature search across PubMed, Embase, Ovid and ResearchGate identified 37 relevant articles, yielding 80 cases after excluding duplicates and irrelevant articles. In analysis, the male‐to‐female ratio for LFE was 5:1, with a mean age of 39 years. Cases were more common among adolescents and older adults (age ≥ 60), with the majority occurring in pubertal adolescents. No racial predilection was observed. The lower back was the most frequently affected site, with rare cases involving other body parts. Some cases were associated with growth spurts or strenuous exercise, although the etiopathogenesis remains speculative. LFE may be underreported due to its asymptomatic nature and resemblance to other skin conditions, particularly striae distensae. Further research is required to clarify its pathogenesis and explore potential treatment options.
- 7 May 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (9) , 1873-1875
Linear focal elastosis: a case report with a brief literature review
Linear focal elastosis (LFE) is an intermittently encountered dermatosis that is often under-recognized and under-reported. Given the unclear aetiopathogenesis and lack of effective treatments, adding more case reports to the literature would contribute to future research. We present a case of LFE in an adolescent boy, describing the findings from dermoscopic examination and updating the epidemiology from a brief literature review.
- 7 May 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (9) , 1873-1875
Linear focal elastosis: a case report with a brief literature review
Linear focal elastosis (LFE) is an intermittently encountered dermatosis that is often under-recognized and under-reported. Given the unclear aetiopathogenesis and lack of effective treatments, adding more case reports to the literature would contribute to future research. We present a case of LFE in an adolescent boy, describing the findings from dermoscopic examination and updating the epidemiology from a brief literature review.
- Open Access
- 3 September 2024
- Published by MDPI AG in Preprints.org
New Therapeutic Approaches for Fibrosing Skin Diseases: An Ecofriendly UVA-1 Permissive Sunscreen Formulation Which Displays Activity at the Aryl Hydrocarbon Receptor. A Potential Cost Effective and Convenient Therapeutic Approach to Fibrosing Skin Di
UVA1 phototherapy has been reported to mediate some of its effects via FICZ/AHR/MAPK signaling. A proof-of-concept study was performed to assess whether a topical solution of L tryptophan formulated to favor the generation 6-formylindolo[3,2-b] carbazole (FICZ) demonstrated activity at the aryl hydrocarbon receptor (AHR) as assessed by the intensity of cytochrome P450 1A2 staining. Ten participants applied a trial agent consisting of L- tryptophan, lecithin, polyvinyl alcohol and ethanol followed by 36 sessions of graduated sun exposure increasing to a total of 20 Joules per square centimetre. At the end of the trial, biopsies were taken from a treated site with photo-protected buttock skin used as a control. Assessment was via intensity of cytochrome P450 1A2 staining. An average baseline value of 53488923 units was obtained at the control site and 972214294 at the treatment site supporting the concept that this preparation displays activity at the AHR. As the components of this preparation are known to have UV absorbing properties and are potentially permissive of UVA-1 transmission, UV absorbance was assessed for natural sunlight and at 365 and 395nm confirming strong absorption in the UVB and UVA-2 spectra with partial transmission in the UVA-1 spectrum.
- 3 September 2024
- Published by MDPI AG in Preprints.org
Open AccessNew Therapeutic Approaches for Fibrosing Skin Diseases: An Ecofriendly UVA-1 Permissive Sunscreen Formulation Which Displays Activity at the Aryl Hydrocarbon Receptor. A Potential Cost Effective and Convenient Therapeutic Approach to Fibrosing Skin Di
UVA1 phototherapy has been reported to mediate some of its effects via FICZ/AHR/MAPK signaling. A proof-of-concept study was performed to assess whether a topical solution of L tryptophan formulated to favor the generation 6-formylindolo[3,2-b] carbazole (FICZ) demonstrated activity at the aryl hydrocarbon receptor (AHR) as assessed by the intensity of cytochrome P450 1A2 staining. Ten participants applied a trial agent consisting of L- tryptophan, lecithin, polyvinyl alcohol and ethanol followed by 36 sessions of graduated sun exposure increasing to a total of 20 Joules per square centimetre. At the end of the trial, biopsies were taken from a treated site with photo-protected buttock skin used as a control. Assessment was via intensity of cytochrome P450 1A2 staining. An average baseline value of 53488923 units was obtained at the control site and 972214294 at the treatment site supporting the concept that this preparation displays activity at the AHR. As the components of this preparation are known to have UV absorbing properties and are potentially permissive of UVA-1 transmission, UV absorbance was assessed for natural sunlight and at 365 and 395nm confirming strong absorption in the UVB and UVA-2 spectra with partial transmission in the UVA-1 spectrum.
- 24 February 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (2) , E121-E124
Primary cutaneous amyloidosis: A review of the available studies and gaps in data
- 24 February 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (2) , E121-E124
Primary cutaneous amyloidosis: A review of the available studies and gaps in data
- 6 July 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 445-446
Olmsted Syndrome: Response to erlotinib therapy and genotype/phenotype correlation
- 6 July 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 445-446
Olmsted Syndrome: Response to erlotinib therapy and genotype/phenotype correlation
- Open Access
- 1 July 2018
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 11, 321-326
Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast
Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast Rowland Noakes Queensland Institute of Dermatology, Greenslopes Private Hospital Campus, Greenslopes, QLD, Australia Background: Scleroderma is traditionally managed with immunomodulatory agents such as methotrexate, mycophenolate mofetil and corticosteroids. There are anecdotal reports for, and theoretical reasons why, the anti-fibrotic agent tranilast may provide an additional treatment modality. Objective: The objective of the current study was to demonstrate if the addition of topical tranilast to an established regime resulted in an improvement in the Localized Scleroderma Assessment Tool (LoSCAT) and modified Rodnan score. Patients and methods: A small double-blinded randomized prospective study of 11 pairs of treatment sites in four patients; three with morphea and one with limited scleroderma was performed. All patients continued with their prescribed treatment and applied 0.1% betamethasone valerate in PCCA PracaSil™ (B) to the control site with 0.1% betamethasone valerate and 1% tranilast (B/T) to the comparator site over a period of 3 months. Photographs and monthly LoSCAT scores were performed on the morphea patients and a modified Rodnan score on the limited scleroderma patient. Statistical analysis was via sign test. Results: The mean baseline LoScat score at the B treated sites was 6.6 which improved to 4.3 (p= 0.16). The mean baseline LoScat score at the B/T treated sites was 5.75 which improved to 2.8 following treatment. (p=0.04) Limitations: This was a small single center study. The ideal concentration of tranilast is unknown. As all patients continued with standard management the expected response may be less than would have been anticipated in a single agent trial. Conclusion: The role of tranilast in the management in scleroderma warrants further investigation in larger trials. Keywords: morphea, limited scleroderma, tranilast, kynurenine
- 1 July 2018
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 11, 321-326
Open AccessAssessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast
Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast Rowland Noakes Queensland Institute of Dermatology, Greenslopes Private Hospital Campus, Greenslopes, QLD, Australia Background: Scleroderma is traditionally managed with immunomodulatory agents such as methotrexate, mycophenolate mofetil and corticosteroids. There are anecdotal reports for, and theoretical reasons why, the anti-fibrotic agent tranilast may provide an additional treatment modality. Objective: The objective of the current study was to demonstrate if the addition of topical tranilast to an established regime resulted in an improvement in the Localized Scleroderma Assessment Tool (LoSCAT) and modified Rodnan score. Patients and methods: A small double-blinded randomized prospective study of 11 pairs of treatment sites in four patients; three with morphea and one with limited scleroderma was performed. All patients continued with their prescribed treatment and applied 0.1% betamethasone valerate in PCCA PracaSil™ (B) to the control site with 0.1% betamethasone valerate and 1% tranilast (B/T) to the comparator site over a period of 3 months. Photographs and monthly LoSCAT scores were performed on the morphea patients and a modified Rodnan score on the limited scleroderma patient. Statistical analysis was via sign test. Results: The mean baseline LoScat score at the B treated sites was 6.6 which improved to 4.3 (p= 0.16). The mean baseline LoScat score at the B/T treated sites was 5.75 which improved to 2.8 following treatment. (p=0.04) Limitations: This was a small single center study. The ideal concentration of tranilast is unknown. As all patients continued with standard management the expected response may be less than would have been anticipated in a single agent trial. Conclusion: The role of tranilast in the management in scleroderma warrants further investigation in larger trials. Keywords: morphea, limited scleroderma, tranilast, kynurenine
- Open Access
- 17 June 2017
- Published by Walter de Gruyter GmbH in Pteridines
- Vol. 28 (2) , 59-66
Dissecting the enigma of scleroderma: possible involvement of the kynurenine pathway
The kynurenine pathway (KP) is the metabolic pathway via which L-tryptophan is converted to nicotinamide. It serves important immune-regulatory roles. This article will review the evidence for involvement of the KP in scleroderma and present a possible model of kynurenine regulation of the cytokine cascade.
- 17 June 2017
- Published by Walter de Gruyter GmbH in Pteridines
- Vol. 28 (2) , 59-66
Open AccessDissecting the enigma of scleroderma: possible involvement of the kynurenine pathway
The kynurenine pathway (KP) is the metabolic pathway via which L-tryptophan is converted to nicotinamide. It serves important immune-regulatory roles. This article will review the evidence for involvement of the KP in scleroderma and present a possible model of kynurenine regulation of the cytokine cascade.
- Open Access
- 1 January 2015
- Published by SAGE Publications in International Journal of Tryptophan Research
- Vol. 8, 7-18
The Aryl Hydrocarbon Receptor: A Review of Its Role in the Physiology and Pathology of the Integument and Its Relationship to the Tryptophan Metabolism
The aryl hydrocarbon receptor (AHR) is a cytosolic receptor for low molecular weight molecules, of which the most widely recognized ligand is 2,3,7,8-tetrachlorodibenzo- p-dioxin (TCDD), and the most widely recognized effect, chloracne. Adverse effects of manipulation were most recently and graphically demonstrated by the poisoning of Viktor Yushchenko during the Ukrainian presidential elections of 2004. However, recent research has revealed a receptor with wide-ranging, and at times, paradoxical actions. It was arguably among the first biological receptors to be utilized by dermatologists, dating from the time of topical tar preparations as a therapeutic agent. I provide a review outlining the role AHR plays in the development, cellular oxidation/antioxidation, responses to ultraviolet light, melanogenesis, epidermal barrier function, and immune regulation and its relationship to tryptophan metabolism. Finally, I will review the role of AHR in diseases of the integument.
- 1 January 2015
- Published by SAGE Publications in International Journal of Tryptophan Research
- Vol. 8, 7-18
Open AccessThe Aryl Hydrocarbon Receptor: A Review of Its Role in the Physiology and Pathology of the Integument and Its Relationship to the Tryptophan Metabolism
The aryl hydrocarbon receptor (AHR) is a cytosolic receptor for low molecular weight molecules, of which the most widely recognized ligand is 2,3,7,8-tetrachlorodibenzo- p-dioxin (TCDD), and the most widely recognized effect, chloracne. Adverse effects of manipulation were most recently and graphically demonstrated by the poisoning of Viktor Yushchenko during the Ukrainian presidential elections of 2004. However, recent research has revealed a receptor with wide-ranging, and at times, paradoxical actions. It was arguably among the first biological receptors to be utilized by dermatologists, dating from the time of topical tar preparations as a therapeutic agent. I provide a review outlining the role AHR plays in the development, cellular oxidation/antioxidation, responses to ultraviolet light, melanogenesis, epidermal barrier function, and immune regulation and its relationship to tryptophan metabolism. Finally, I will review the role of AHR in diseases of the integument.
- Open Access
- 1 January 2013
- Published by SAGE Publications in International Journal of Tryptophan Research
- Vol. 6, 97-102
Immunohistochemical Studies of the Kynurenine Pathway in Morphea
Cutaneous sclerosis, resembling that seen in subcutaneous morphea, is a feature of eosinophilic fasciitis and eosinophilia-myalgia syndrome, two conditions in which the kynurenine pathway is known to be activated. To investigate the possibility of activation of the kynurenine pathway in morphea, skin biopsies were taken from involved and non-involved sites in a series of three patients with morphea. Immunohistochemical stains for quinolinic acid and indoleamine 2,3-dioxygenase (IDO) were performed.
- 1 January 2013
- Published by SAGE Publications in International Journal of Tryptophan Research
- Vol. 6, 97-102
Open AccessImmunohistochemical Studies of the Kynurenine Pathway in Morphea
Cutaneous sclerosis, resembling that seen in subcutaneous morphea, is a feature of eosinophilic fasciitis and eosinophilia-myalgia syndrome, two conditions in which the kynurenine pathway is known to be activated. To investigate the possibility of activation of the kynurenine pathway in morphea, skin biopsies were taken from involved and non-involved sites in a series of three patients with morphea. Immunohistochemical stains for quinolinic acid and indoleamine 2,3-dioxygenase (IDO) were performed.